Sanofi Genzyme, PerkinElmer Launch Free Dx Program for Patients With Lysosomal Storage Disorders

Oct 15, 2018

|

NEW YORK (GenomeWeb) – Sanofi's Genzyme subsidiary and PerkinElmer Genomics, the molecular genetics laboratory of PerkinElmer, have launched a program called the Lantern Project to provide no-cost diagnostic testing to patients in the US who suffer from certain lysosomal storage disorders (LSDs).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Sanofi Genzyme, PerkinElmer Launch Free Dx Program for Patients With Lysosomal Storage Disorders

To read the full story....

Breaking News

BARDA Awards $684K to Luminex for Enhanced COVID-19 Multiplex Antibody Test

Vela Diagnostics Receives Second FDA Emergency Use Authorization for SARS-CoV-2 Molecular Test

Centogene Reports 13 Percent Decline in Q2 Revenues

Becton Dickinson Submits Premarket Approval Supplement to FDA for HPV Assay

BioReference Settles False Claims, Kickback Allegations for $11.5M

Quest, Walmart Teaming Up to Deliver SARS-CoV-2 Home Sampling Kits Via Drone

Featured White Papers

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

What's Popular?

BioReference Settles False Claims, Kickback Allegations for $11.5M

UBS Downgrades Illumina to Neutral; Expresses Doubts About Grail Deal

Becton Dickinson Submits Premarket Approval Supplement to FDA for HPV Assay

FDA Grants Emergency Use Authorization for GK Pharmaceuticals Coronavirus Test

Grail Deal Will Enable Illumina to Expand From Tech Innovator to Diagnostics Provider

Sponsorships